Management of medication errors in oncological patients: A cross-sectional study and case reports of pharmaceutical interventions in a university hospital in central-west Brazil [0.03%]
巴西中西部大学医院肿瘤患者用药错误的管理：药学干预的横断面研究和病例报告
Esther Domenici Mozzer Pontes,Renato Rocha Martins,Paulo Augusto Souza Fernandes et al.
Esther Domenici Mozzer Pontes et al.
IntroductionAntineoplastic chemotherapy (ACT) is widely used, but involves significant risks due to protocol complexity and inherent toxicity. Pharmacists play a key role in validating ACT prescriptions to enhance patient safety.ObjectiveTo...
Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia [0.03%]
急性髓系白血病患者抗菌药物预防性应用及感染的回顾性分析
Jeffrey Jang,Timothy Nold,Joseph P Marshalek et al.
Jeffrey Jang et al.
Introduction: Patients with acute myeloid leukemia (AML) are immunocompromised as a result of their malignancy and treatment, which can predispose to infection. The incidence of bacterial infection is most common (75-80%), followed by funga...
Immune checkpoint inhibitor-induced hyperthyroidism: Incidence, risk factors, and clinical outcomes in a real-world cohort study [0.03%]
免疫检查点抑制剂诱导的甲状腺功能亢进症：一项真实世界队列研究中的发病率、危险因素和临床结局
Baqir Jafry,Farzeen Syed,Jennifer Collins et al.
Baqir Jafry et al.
BackgroundHyperthyroidism is an immune-related adverse event associated with ICI use. Its underlying risk factors, progression to thyroiditis, and impact on patient outcomes remain less understood.MethodsData were obtained from the TriNetX ...
From needs to app: A user-centred design approach for developing mobile health interventions in oncology care [0.03%]
从需求到应用：肿瘤护理中移动医疗干预的以用户为中心的设计方法
G Hari Prakash,Sunil Kumar D,Vanishri Arun et al.
G Hari Prakash et al.
BackgroundChemotherapy management presents multi-dimensional challenges, including severe side effects, treatment non-adherence, and psychological distress, particularly in low- and middle-income countries where healthcare access and digita...
Modified monitoring of abiraterone acetate-induced hepatotoxicity in prostate cancer patients [0.03%]
阿比特龙致肝毒性的监测方法在前列腺癌患者中的优化应用
Sweta Mishra,Hannah Spencer,Katherine Kelly
Sweta Mishra
IntroductionAbiraterone is a standard treatment for prostate cancer and is a preferred treatment option at the Veterans Affairs North Texas Health Care System (VANTXHCS) due to its formulation, cost, and overall tolerability. In the combine...
Nutrition support pharmacy practices in hospitalized cancer patients admitted to bone marrow transplant units: A 3-year retrospective analysis of clinical nutrition support pharmacists' interventions [0.03%]
临床营养支持药师干预入组骨髓移植病房的住院癌症患者营养支持药学实践的3年回顾性分析
Nadine N Abdelhadi,Ala&#x;a Dabbous,Mariam Darwish et al.
Nadine N Abdelhadi et al.
BackgroundFew studies have investigated nutrition support pharmacy practices and interventions in bone marrow transplant units. This study aimed to analyze the interventions of clinical nutrition support pharmacists in hospitalized cancer p...
Co-reported respiratory adverse events in trastuzumab deruxtecan-associated interstitial lung disease: A pharmacovigilance analysis of the FAERS database [0.03%]
基于FAERS数据库的德喜曲妥珠单抗相关间质性肺病共报告呼吸不良事件：一项药物警戒学分析
Seda Jeral Evinç,Çağla Eyüpler Akmercan,Zeliha Birsin et al.
Seda Jeral Evinç et al.
BackgroundTrastuzumab deruxtecan (T-DXd) is an effective HER2-directed antibody-drug conjugate used across multiple solid tumors. Interstitial lung disease (ILD) and pneumonitis are well-recognized as clinically significant toxicities assoc...
Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel [0.03%]
加拿大专家小组的见解：关于抗体药物偶联物致恶心呕吐的管理建议
Katarzyna J Jerzak,Stephanie Snow,Jan-Willem Henning et al.
Katarzyna J Jerzak et al.
ObjectiveTrastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) that are associated with clinically significant antineoplastic-induced nausea and vomiting (AINV), for which prophylaxis and manageme...
Immunotherapy "stop and go" and early discontinuation: A viable option in limited resources setting [0.03%]
免疫治疗的“启动与停止”及早期停药：资源有限条件下的可行选择
Nesrine Mejri,Myriam Saadi,Saif Baklouti et al.
Nesrine Mejri et al.
BackgroundImmunotherapy (IO) has transformed cancer treatment, improving survival across various malignancies. However, optimal treatment duration and dosing regimens remain unclear. In low- and middle-income countries like Tunisia, access ...